Press Releases

TEL AVIV, Israel--(BUSINESS WIRE)-- Elron Electronic Industries Ltd. (NASDAQ: ELRN) (TASE: ELRN), today announced that further to its announcement on May 20, 2009, Elron intends to negotiate with Clal Industries and Investments Ltd. ("Clal") and Discount Investment Corporation Ltd. ("DIC") regarding a transaction whereby Clal and DIC will acquire from Elron, its approximately 15% interest in NetVision Ltd. (TASE: NTSN), a provider of communication services in Israel. The price of Elron's interest in Netvision will be determined by negotiation between the parties based on an appraisal of such interest to be prepared, and for that purpose, an independent appraiser was today jointly appointed by the parties. In addition, Elron intends to engage an independent expert to express an opinion as to the fairness for Elron of the price to be determined.

DIC currently holds approximately 49% of Elron's outstanding ordinary shares. DIC and Clal are both majority owned subsidiaries of IDB Development Ltd. DIC and Clal currently hold approximately 31% and 24%, respectively, of Netvision's outstanding ordinary shares. Elron, DIC and Clal are parties to a shareholders agreement in connection with their respective holdings of Netvision shares.

The transaction is subject to the parties reaching and entering into a definitive agreement as well as obtaining applicable corporate and regulatory approvals and there is no assurance of the occurrence, timing or terms of such transaction.

Elron Electronic Industries Ltd. (TASE & NASDAQ: ELRN), a member of the IDB Holding group, is a high-technology holding company traded in the Nasdaq and in the Tel-Aviv Stock Exchange. Elron's group companies currently comprise a diverse range of publicly-traded and privately held companies primarily in the fields of medical devices, information & communications technology, clean technology and semiconductors. Included in our group companies are well established companies who are leaders in their fields, such as Given Imaging and 013 NetVision, together with innovative start-up companies who possess growth potential in Israel and the rest of the world. For further information, please visit www.elron.com.

Any statements in this press release that may be considered forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to the impact of: the global financial crisis and economic downturn on Elron and its group companies, any decrease in the market value of Given Imaging, the continuing losses incurred by certain group companies, the need of Elron's group companies for additional capital in order to reach profitability, the possibility of further impairment charges and other risk factors detailed from time to time in the Company's Annual Report on Form 20-F and other periodic reports filed by the Company with the Securities and Exchange Commission, which the Company urges investors to consider. The restricted availability of financing for young technology companies, the limited availability of profitable "exits" and the increased volatility in the securities markets may affect our business results and compliance with bank covenants. Elron assumes no obligation to update the information in this press release and disclaims any obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Reference to Elron's website above does not constitute incorporation of any of the information thereon into this press release.

    Source: Elron Electronic Industries Ltd.

JOLIETTE, QUEBEC--(Marketwire - July 5, 2009) - On behalf of the Honourable James Moore, Minister of Canadian Heritage and Official Languages, and of the Honourable Denis Lebel, Minister of State (Economic Development Agency of Canada for the Regions of Quebec), the Honourable Michel Rivard, Senator, today announced funding for the Festival de Lanaudiere.

"The Government of Canada is pleased to support the Festival de Lanaudiere, which continues to grow in popularity and attract lovers of classical music from near and far," said Minister Moore. "This gathering expresses all the wealth of the classical music world and contributes to the cultural vitality of the region and all of Quebec."

"The diversity, richness, and originality of classical music are no doubt behind the hundreds of thousands of visitors who attend the Festival international de Lanaudiere every year," said Minister of State Lebel. "Its success, combined with the $5 million in annual economic spin-offs, has a major impact on the entire region. Through this contribution, Canada Economic Development aims to support Quebec's incredible cultural and artistic vitality and to make our communities more dynamic through tourism development."

"I would like to pay tribute to the work and legacy of the late Father Lindsay, founder of the Festival de Lanaudiere. Thanks to him, magnificent concerts are presented not only in the Amphitheatre de Lanaudiere in Joliette, but also in a number of neighbouring communities," said Senator Rivard.

The Festival de Lanaudiere promotes the creation, development, and production of top-quality artistic performances presented in unique contexts. The 32nd edition of this international-calibre event, which is taking place this year from July 4 to August 2, provides a showcase for artists from Canada and other countries and offers a program of more than 70 concerts to music lovers in the Lanaudiere region, elsewhere in the country, and around the world.

The Government of Canada has provided $300,000 in funding through the Arts Presentation Canada program of the Department of Canadian Heritage. This program gives Canadians increased access to the diversity and richness of Canada's culture through professional arts festivals, presentations of live professional performances, and other artistic experiences.

The Government of Canada has also provided a non-refundable contribution of $306,375 through Canada Economic Development for the 2008, 2009, and 2010 editions of the Festival. These funds, which come from the Community Diversification program, will be used to finance promotional efforts in Canadian and foreign markets.

This news release is available on the Internet at www.canadianheritage.gc.ca under Media Room.

Canada Economic Development is online at www.dec-ced.gc.ca. Subscribe to its news releases at www.dec-ced.gc.ca/eng/salle-medias/liste-envoi/envoi.html and stay up to date on the latest news.

FOR FURTHER INFORMATION PLEASE CONTACT:
        Office of the Minister of Canadian Heritage and
        Official Languages
        Stephanie Rea
        819-997-7788

        Canadian Heritage
        Eric Amyot
        Director, Regional Communications
        Quebec Region
        514-283-4027

        Canadian Heritage
        Media Relations
        819-994-9101
        1-866-569-6155

        Canada Economic Development
        Marie-Claude Lemire
        Communications
        514-283-2199
        marie-claude.lemire@dec-ced.gc.ca

        Office of the Minister of State (Economic Development
        Agency of Canada for the Regions of Quebec)
        Eric Lefebvre
        Senior Special Assistant, Communications
        613-608-7906
        eric.lefebvre@dec-ced.gc.ca

Source: Canadian Heritage

JERUSALEM--(BUSINESS WIRE)-- Hadasit, the technology transfer company of Hadassah University Medical Center, announced that Jerusalem Mayor Nir Barkat visited the new Hadassah Medical Center Hebrew University Biotechnology Park (JBP-Jerusalem BioPark) Ein-Kerem at Hadassah University Hospital's Ein Kerem campus today.

The visit coincided with the mayor's June 15th announcement to invest NIS 100 million in the development of the capital's biomedical industry over the next five years to create jobs and attract local and foreign businesses to establish a presence in the city. The JBP is a cornerstone of this plan and is heralded as first of its kind in Israel.

Mayor Barkat said, "The municipality and the Jerusalem Development Authority are available to the JBP and support plans to extend the Jerusalem light rail train to the BioPark and Hadassah Ein Kerem campus."

He continued, "Hadassah University Medical Center is a world class medical facility; Hadasit is a novelty amongst technology transfer companies, and Hadasit Bio Holdings (HBL), its publicly traded subsidiary, adds additional elements of attraction for the investment community such as liquidity, transparency and diversity. Hebrew University is a prime academic institution. Indeed there is much potential here."

Mayor Barkat concluded, "Hadassah, Hadasit, HBL and HU have successfully pushed boundaries and pioneered new terrain in terms of the marriage of science and business. Today, we bear witness to a vision realized, the beginnings of a thriving biopark, the essential infrastructure element to compliment the existing innovation and commercialization programs already in place. It is a great pride that all of the scientific creativity and commercial progress at the Hadassah Ein Kerem campus is attracting global interest."

The mayor's visit at JBP was hosted by Professor Shlomo Mor-Yosef, Director General of Hadassah Medical Organization and chairman of the board of Hadasit. The visit was attended by Elchanan HaCohen, vice president & director general of the Hebrew University of Jerusalem, Avraham Kuznitsky, founder and owner of Minrav, the heads of the departments at Hadassah University Hospital Ein Kerem, the CEO and chairman of HBL, chief scientific officers of HBL's nine portfolio companies, including Cell Cure, Thrombotech, ConjuGate, TKsignal, InCure, ProtAb, Tolarex, Verto, and KAHR Medical, as well as the staff of the HCRC.

Professor Mor-Yosef said, "Mayor Barkat, we hope that you will join the efforts of bringing additional businesses to the JBP by introducing incentives."

"It is an honor to host you today Mr. Mayor. Your firm commitment to supporting and growing the life science industry in Jerusalem is an inspiration to all of us, and especially, the hard working scientists and company CEOs who have already chosen to innovate at the Jerusalem BioPark," said Dr. Rafi Hofstein, chairman of the board of HBL.

Mr. HaCohen said, "The massive infrastructure within the campus and the combination of the Hebrew University and Hadassah Medical Center are ideal for leveraging the economic and scientific capabilities of Jerusalem, especially in high tech where Jerusalem enjoys a relative advantage."

The JBP, a joint project of Hadassah and the Hebrew University, was constructed by Minrav, one of Israel's leading real estate developers. The facility, which just recently opened it doors, comprises customized offices and access to Hadassah's state of the art Clinical Research Center (HCRC) which provides pharmaceutical, biotechnology and medical device companies a complete package of services and facilities for drug and device clinical studies. HCRC services include the availability of Hadassah's dedicated, top rate, GCP qualified clinical team, a large patient pool, a certified GMP facility and a research center with standard operating procedures (SOP's) to ensure quality control. JBP is also intended to be a center where occupants may benefit from the massive pool of expertise and innovation within Hadassah Medical Center, the hospital with the highest rate of translational R&D in Israel, as well as the free flow of ideas and symbiotic collaborations.

About Hadasit and HBL

Hadasit (www.hadasit.co.il), the technology transfer company of Hadassah Medical Organization (HMO) in Jerusalem, Israel, promotes and commercializes HMO's continuously generated intellectual property (IP) and R&D capabilities. IP generated by HMO has already gained global recognition due to Hadasit's successful enterprising of Hadassah's biomedical technology, including novel therapeutics, diagnostics and devices.

Hadasit Bio Holdings (TASE: HDST), (www.hbl.co.il), is the publicly traded holding company of Hadasit, the technology transfer company of Hadassah Medical Organization. HBL was founded in 2005 for the purpose of advancing the knowledge and experience accumulated in the Hadassah University Hospital Research Laboratories. HBL has a portfolio of nine biotechnology companies, all of which have proven success at the feasibility stage; all have demonstrated efficacy of a medication/s in animal models and are before clinical trials. HBL's companies are all developing medications for billion dollar markets and have blockbuster potential. Fields of focus include cancer, inflammatory diseases and tissue rehabilitation by means of stem cells, all of which Hadassah University Hospital possesses vast knowledge and is known as a world leader. The company was issued in January 2006 and raised up to date approximately 20 million dollars from the public and from a strategic investor.

About Hadassah University Medical Center

The Hadassah University Medical Center (www.hadassah.org.il) is a state-of-the-art medical center incorporating all medical and surgical sub-specialties. With a 750 beds tertiary care referral hospital at Ein Kerem and a 300 bed community hospital on Mt. Scopus, Hadassah University Medical Center in Jerusalem conducts half of the hospital research in Israel. The flagship of Hadassah, the Women's Zionist Organization of America, which laid the foundation of Israel's medical infrastructure, initiated and maintains educational programs and youth institutions, and is the main supporter of The Hadassah Medical Center, which is committed to excellence in health care, medical research and medical education. Together with the Hebrew University, Hadassah runs five academic schools of medical professions. Hadassah treats everybody, regardless of race, religion, gender, ethnicity or political persuasion, and provides medical services to nearly one million people annually.

About Hadassah Clinical Research Center

The Hadassah Clinical Research Center (HCRC) is the Phase I Clinical Trial Unit of the Hadassah University Hospital located at The Hadassah Medical Center Hebrew University Biotechnology Park (JBP-Jerusalem BioPark) Ein-Kerem. The HCRC is a joint venture of the Clinical Pharmacology Unit of the Division of Medicine and Hadasit, the technology transfer company of Hadassah University Hospitals. Professor Yoseph Caraco, a clinical pharmacologist with an international reputation in clinical and laboratory research, leads a dedicated team of professionals trained to conduct research with the highest international standards. The staff at the 15 bed HCRC unit has years of experience working with local and international pharmaceutical, biotechnology, medical device and CRO companies, offering a complete package of services and facilities for drug and device clinical studies. For more information about the HCRC, please contact: liron@hadassah.org.il.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6000448&lang=en

    Source: Hadasit

LEEDS, England, July 5 /PRNewswire/ -- bwin.com, the official sponsor of Real Madrid, will be providing live and exclusive online streaming of Cristiano Ronaldo's official unveiling as a Real Madrid player on Monday 6th July.

bwin.com will be the only place where supporters will be able to see the live unveiling of the reigning FIFA World Player of the Year as he completes his world record GBP80m move from Manchester United to the Bernabeu.

Ronaldo, who scored an incredible 117 goals in 242 starts during his time at Old Trafford, become the world's most expensive player, eclipsing the GBP56million Real paid of Brazilian midfielder Kaka earlier this summer.

To view the live and exclusive online stream, visit www.bwin.com at 7:30pm (GMT) on Monday 6th July.

bwin.com is the official sponsor of Real Madrid, AC Milan and FC Bayern Munich.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE bwin.com

OTTAWA, ONTARIO--(Marketwire - July 5, 2009) -

A correction from source is being issued with respect to the release sent out today at 9:32 AM EDT. The media will "not be permitted on the tarmac" instead of "being permitted on the tarmac". The corrected version follows.

Our fallen soldier, Corporal Nick Bulger from the 3rd Battalion, Princess Patricia's Canadian Light Infantry based in Edmonton, returns home to Canada tomorrow.

Where: 8 Wing, Canadian Forces Base Trenton, Ontario.

When: Monday, July 6, 2009 at 2:00 p.m.

What: At the request of the family, media will not be permitted on the tarmac.

Present to pay their respects will be the Minister of National Defence, The Honourable Peter MacKay, Chief of the Defence Staff, General Walt Natynczyk and other dignitaries.

Corporal Bulger was killed when an improvised explosive device detonated near an armoured vehicle during a patrol in the Zhari District. The incident occurred south-west of Kandahar City at around 11:20 a.m., Kandahar time, on July 3, 2009.

Five other Canadian soldiers were injured.

FOR FURTHER INFORMATION PLEASE CONTACT:
        Interested media may contact Captain Mark Peebles
        8 Wing/CFB Trenton Public Affairs Officer
        613-392-2811, ext. 2041
        peebles.m@forces.gc.ca

        For general queries:
        Media Liaison Office
        1-866-377-0811 or 613-996-2353, or on weekends 613-792-2973

        For flight information:
        Air Passenger Terminal
        1-800-487-1186

Source: Department of National Defence